Company intelligence / Profile preview
Zhejiang Echon Biopharm
Zhejiang Sheng, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Zhejiang Echon Biopharm Limited, founded in China in 2017, develops recombinant polypeptide drugs with a primary focus on infectious, respiratory, and oral/mucosal diseases. Its lead asset GB001 recombinant peptide spray targets mild recurrent aphthous ulcer and has reached Phase IIa clinical trials as of early/mid–2025. The company appears to have at least two pipeline programs but detailed results are not publicly available. No major licensing deals or partnerships are disclosed.
- Therapeutic areas
- OtherGastroenterologyPulmonologyInfectious Diseases
- Modalities
- Recombinant polypeptideRecombinant peptidePeptide (as a general class)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Zhejiang Echon Biopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Echon Biopharm.